NFATC1 and osteoporosis: In conclusion, our study demonstrated for the first time that the MCU inhibitor RR was able to inhibit osteoclast formation and bone resorption by inhibiting ROS, P38 MAPK, and NFATc1 and validated its potential therapeutic effects in osteoporosis animal models.